GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.
- GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.
- ACLF is a potentially deadly, but reversible, condition in patients with chronic liver diseases, which is associated with multi-organ failure and high short-term mortality.
- Pascal Prigent, CEO of GENFIT, commented: “During AASLD we were excited to further discuss our development strategy around our new pipeline focused on ACLF, where we believe multiple programs have the potential to transform the treatment paradigm for these patients.
- As part of the “ACLF Day” event during AASLD, the critical need for treatment has been highlighted by leading experts in ACLF.